CN101448800A - 作为大麻素受体配体的新型化合物及其用途 - Google Patents

作为大麻素受体配体的新型化合物及其用途 Download PDF

Info

Publication number
CN101448800A
CN101448800A CNA2007800186013A CN200780018601A CN101448800A CN 101448800 A CN101448800 A CN 101448800A CN A2007800186013 A CNA2007800186013 A CN A2007800186013A CN 200780018601 A CN200780018601 A CN 200780018601A CN 101448800 A CN101448800 A CN 101448800A
Authority
CN
China
Prior art keywords
methane amide
thiazoles
fork base
diamantane
methoxy ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800186013A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·达特
W·A·凯罗尔
A·S·弗洛尔詹奇克
J·M·弗罗斯特
M·E·加拉赫尔
T·科拉萨
李彤梅
D·W·奈尔逊
M·V·帕特尔
S·佩迪
A·佩雷斯-梅德拉诺
K·B·赖瑟
K·R·蒂特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN101448800A publication Critical patent/CN101448800A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
CNA2007800186013A 2006-05-31 2007-05-31 作为大麻素受体配体的新型化合物及其用途 Pending CN101448800A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80961506P 2006-05-31 2006-05-31
US60/809,615 2006-05-31

Publications (1)

Publication Number Publication Date
CN101448800A true CN101448800A (zh) 2009-06-03

Family

ID=38645597

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800186013A Pending CN101448800A (zh) 2006-05-31 2007-05-31 作为大麻素受体配体的新型化合物及其用途

Country Status (8)

Country Link
US (3) US7875639B2 (es)
EP (1) EP2024349B1 (es)
JP (1) JP2009538933A (es)
CN (1) CN101448800A (es)
CA (1) CA2647598A1 (es)
ES (1) ES2645995T3 (es)
MX (1) MX2008015214A (es)
WO (1) WO2007140439A2 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109574856A (zh) * 2018-12-07 2019-04-05 无锡福祈制药有限公司 一种新的金刚乙胺类似物及其合成方法
CN110172067A (zh) * 2019-04-11 2019-08-27 河南科技大学第一附属医院 一种具有杀菌活性的噻唑类药物分子及其制备方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
JP2009538931A (ja) * 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしてのチアゾール化合物およびそれの使用
EP2024349B1 (en) * 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8158663B2 (en) 2006-12-22 2012-04-17 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
EP2142522A1 (en) 2007-03-28 2010-01-13 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
MX2009012374A (es) * 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
MX2010005649A (es) * 2007-11-21 2010-08-18 Abbott Lab Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
WO2009114566A1 (en) 2008-03-11 2009-09-17 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8173687B2 (en) * 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2334646A2 (en) 2008-09-16 2011-06-22 Abbott Laboratories Substituted benzamides as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
WO2011090935A1 (en) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
MY173280A (en) 2012-12-21 2020-01-10 Janssen Sciences Ireland Uc Antibacterial compounds
WO2015012210A1 (ja) * 2013-07-23 2015-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
US10653681B2 (en) 2016-03-16 2020-05-19 Recurium Ip Holdings, Llc Analgesic compounds

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1522361A1 (de) 1966-03-08 1969-07-24 Agfa Gevaert Ag Sensibilisierung lichtempfindlicher Polymerer
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
DE1772867A1 (de) 1968-07-15 1971-06-16 Agfa Gevaert Ag Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren
JPS5089367A (es) 1973-12-14 1975-07-17
JPS57171986A (en) 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
DE3333450A1 (de) 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
US4885295A (en) 1984-08-06 1989-12-05 Sterling Drug Inc. Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
US4978664A (en) 1984-08-06 1990-12-18 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions
DE3533331A1 (de) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3807381A1 (de) 1988-03-07 1989-09-21 Hoechst Ag 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt
TW205041B (es) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4021439A1 (de) 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridin-derivate
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
WO1992015564A1 (en) 1991-03-11 1992-09-17 Nippon Soda Co., Ltd. Novel heterocyclic compound
BR9306011A (pt) 1992-03-03 1997-10-21 Idemitsu Kosan Co Derivados de pirazol
EP0568096B1 (en) 1992-04-30 1998-07-29 Hodogaya Chemical Co., Ltd. Benzothiazole derivative and agricultural and horticultural fingicide composition containing the same
US5654322A (en) 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
WO1994022821A1 (en) 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH06345736A (ja) 1993-06-14 1994-12-20 Tokuyama Soda Co Ltd ウレタン化合物を製造する方法
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
AU2641295A (en) 1994-05-17 1995-12-05 Dowelanco N-(5-isothiazolyl)amide pesticides
ES2340142T3 (es) 1994-07-08 2010-05-31 Ev3 Inc. Sistema para llevar a cabo un procedimiento intravascular.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
CA2283925A1 (en) * 1997-03-24 1998-10-01 Basf Aktiengesellschaft Thiazolimine derivatives
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
CA2370265A1 (en) 1999-04-20 2000-10-26 Syngenta Limited Pesticidal indazole or benzotriazole derivatives
DE19928033A1 (de) 1999-06-18 2000-12-21 Basf Ag Verwendung von cyclischen Enaminen als Lichtschutzmittel
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
DE60011100T2 (de) 1999-08-27 2005-06-16 Abbott Laboratories, Abbott Park Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
CN1247553C (zh) 1999-09-14 2006-03-29 盐野义制药株式会社 2－亚氨基－1,3－噻嗪衍生物
AU1095101A (en) 1999-10-18 2001-04-30 University Of Connecticut, The Cannabimimetic indole derivatives
GB0002034D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0006289D0 (en) * 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0010437D0 (en) 2000-04-28 2000-06-14 Darwin Discovery Ltd Process
EP1300401B1 (en) 2000-06-30 2009-12-09 Dainippon Sumitomo Pharma Co., Ltd. Thiazole derivatives for use as antiinflammatories
US6369052B1 (en) * 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1363632B1 (en) 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US20030008807A1 (en) 2001-06-14 2003-01-09 The Regents Of The University Of California Novel signaling pathway for the production of inflammatory pain and neuropathy
US7949668B2 (en) 2001-08-20 2011-05-24 Pardalis, Inc. Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain
US20040259912A1 (en) 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
US7183288B2 (en) * 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
WO2003057693A1 (fr) * 2001-12-28 2003-07-17 Sumitomo Pharmaceuticals Co., Ltd. Composes cycliques a 5 chainons
IL165217A0 (en) * 2002-05-16 2005-12-18 Bayer Cropscience Gmbh Pesticidal pyridinecarboxamide derivatives
JP3902523B2 (ja) 2002-08-05 2007-04-11 富士フイルム株式会社 光情報記録媒体および情報記録方法
US20040077617A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Fused cycloalkyl amides and acids and their therapeutic applications
FR2847899B1 (fr) 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
US7390670B2 (en) 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20070105908A1 (en) 2003-06-27 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd. Thiazolimine compound and oxazolimine compound
WO2005023818A2 (en) 2003-09-10 2005-03-17 Gpc Biotech Ag Heterobicyclic compounds as pharmaceutically active agents
CN100509808C (zh) * 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US20080312435A1 (en) * 2004-11-15 2008-12-18 Taisho Pharmaceutical Co., Ltd. Imine Compound
EP1833824B1 (en) 2004-12-21 2016-08-03 AbbVie Inc. 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands
FR2880023B1 (fr) 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US7872006B2 (en) 2005-10-21 2011-01-18 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
JP2009538931A (ja) 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしてのチアゾール化合物およびそれの使用
EP2024349B1 (en) * 2006-05-31 2017-08-02 AbbVie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CA2659762A1 (en) 2006-06-27 2008-01-03 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
WO2008028094A1 (en) 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
WO2008028093A1 (en) 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
US8158663B2 (en) 2006-12-22 2012-04-17 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
EP2142522A1 (en) 2007-03-28 2010-01-13 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
KR20100105802A (ko) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
MX2010005649A (es) 2007-11-21 2010-08-18 Abbott Lab Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
WO2009114566A1 (en) 2008-03-11 2009-09-17 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8173687B2 (en) 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2334646A2 (en) 2008-09-16 2011-06-22 Abbott Laboratories Substituted benzamides as cannabinoid receptor ligands
WO2010054024A2 (en) 2008-11-04 2010-05-14 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
CA2756178A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8236822B2 (en) 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109574856A (zh) * 2018-12-07 2019-04-05 无锡福祈制药有限公司 一种新的金刚乙胺类似物及其合成方法
CN110172067A (zh) * 2019-04-11 2019-08-27 河南科技大学第一附属医院 一种具有杀菌活性的噻唑类药物分子及其制备方法
CN110172067B (zh) * 2019-04-11 2021-06-15 河南科技大学第一附属医院 一种具有杀菌活性的噻唑类药物分子及其制备方法

Also Published As

Publication number Publication date
ES2645995T3 (es) 2017-12-11
US20080064699A1 (en) 2008-03-13
US7875639B2 (en) 2011-01-25
US20150231141A1 (en) 2015-08-20
MX2008015214A (es) 2008-12-12
WO2007140439A2 (en) 2007-12-06
JP2009538933A (ja) 2009-11-12
CA2647598A1 (en) 2007-12-06
EP2024349B1 (en) 2017-08-02
US20110086855A1 (en) 2011-04-14
WO2007140439A3 (en) 2008-01-24
US9006275B2 (en) 2015-04-14
EP2024349A2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
CN101448800A (zh) 作为大麻素受体配体的新型化合物及其用途
CN101454302A (zh) 用作大麻素受体配位体的噻唑化合物及其用途
TWI291465B (en) Heterocyclic dihydropyrimidine compounds
CN105121432B (zh) 作为激酶抑制剂的杂环酰胺
CN102822165B (zh) 芳基甲氧基异吲哚啉衍生物和包括其的组合物及它们的使用方法
CN102083312B (zh) 苯磺酰胺噻唑和噁唑化合物
CN101765593A (zh) 用作大麻素受体配体的2-亚氨基异噻唑衍生物
JP6624594B2 (ja) 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体
CN101263107A (zh) 作为二肽基肽酶-iv(dpp-iv)抑制剂的药物组合物
CN101925300A (zh) 作为大麻素受体配体的新化合物和其用途
CN101743223A (zh) 用作大麻素受体配体的新化合物
CN104220422B (zh) Ep1受体配体
CN102036984A (zh) 作为大麻素受体配体的新化合物
CA2677296A1 (en) Therapeutic agents
CN102666489B (zh) 鞘氨醇激酶抑制剂
CN101711253A (zh) 用作大麻素受体配体的新化合物
CN101573357A (zh) 吲哚化合物
CN101636155A (zh) 二酰甘油o-酰基转移酶1型酶的抑制剂
JP2023513272A (ja) ヘテロ環ｇｌｐ－１アゴニスト
ES2685923T3 (es) Composición medicinal para mejorar la función cerebral
CN101820868A (zh) 作为大麻素受体配体的新化合物
JPWO2008091021A1 (ja) ヘテロシクリデン−ｎ−（アリール）アセトアミド誘導体
CN102448957A (zh) 作为大麻素受体配体的化合物
CN102123993A (zh) 作为大麻素受体配体的亚胺衍生物
CN1972913A (zh) 四氢吡喃基环戊基四氢吡啶并吡啶趋化因子受体活性调节剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090603